** Shares of drug developer Plus Therapeutics PSTV.O more than double to 38 cents

** Co says the U.S. FDA has cleared its application to begin human trials for its experimental brain cancer therapy

** The trial is funded by a $3 million research grant from the U.S. Department of Defense, co says

** The early-stage trial is aimed to determine the maximum tolerated dose safety and tolerability of the therapy called Reyobiq in pediatric patients aged six to 21 years

** The company is testing the therapy to treat aggressive brain tumors called high-grade glioma and ependymoma

** Including session moves, stock down 68.1% YTD

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))